Opfolda (Miglustat)

Miglustat, the active ingredient in Opfolda, is a Iminosugar (glucosylceramide synthase inhibitor) presented as a tablet for oral use. It treats Niemann-Pick disease type C and Gaucher disease type 1 in patients requiring substrate reduction therapy.

GNH USA supplies Opfolda as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Opfolda provides substrate reduction therapy for lysosomal storage disorders.

- Niemann-Pick disease type C: reduces cholesterol and glycosphingolipid accumulation, improving neurological and systemic symptoms. - Gaucher disease type 1: decreases substrate buildup in macrophages, alleviating organ enlargement and hematologic abnormalities.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease or urge to vomit. - Weight loss: gradual reduction in body weight. - Tremor: mild, fine shaking of the hands.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Severe allergic reactions: rash, swelling, or difficulty breathing. - Hepatic dysfunction: elevated liver enzymes or jaundice.

Patients should be monitored for metabolic and gastrointestinal effects, and dosage adjustments may be required based on tolerance.

- Monitor blood glucose: miglustat can affect carbohydrate metabolism. - Assess liver function: periodic liver enzyme testing is advised. - Evaluate renal function: dose may need adjustment in renal impairment. - Counsel on diet: high‑carbohydrate meals may exacerbate gastrointestinal symptoms. - Avoid in severe hepatic disease: contraindicated where liver function is markedly compromised. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Miglustat may interact with drugs that influence its absorption or metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may significantly reduce miglustat exposure. - Antidiabetic agents (e.g., insulin, sulfonylureas): increased risk of hypoglycemia. - Warfarin: potential for enhanced anticoagulant effect.

Moderate Interactions (Monitor Closely): - Oral contraceptives: miglustat may lower contraceptive efficacy. - Other gastrointestinal motility agents: additive effects on diarrhea. - Antiepileptic drugs (e.g., carbamazepine): may alter miglustat plasma levels.